Evidence map›Paper›PMID 34427738›Full record

ArticleAnnals of hematology2021

Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.

Kouichi Ohya, Shuhei Okuyama, Shin-Ya Ogata, Kunihiko Maeda, Kyohei Yamada, Kouichi Ohshima, Katsushi Tajima

Abstract readCase ReportsLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kouichi OhyaDepartment of Hematology, Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan.
Shuhei OkuyamaDepartment of Hematology, Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan.
Shin-Ya OgataDepartment of Pathology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Kunihiko MaedaDepartment of Physical Therapy, Yamagata Prefectural University of Health Sciences, Yamagata, Japan.
Kyohei YamadaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Kouichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume, Japan.
Katsushi TajimaDepartment of Hematology, Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan. katsushitajima@ypch.gr.jp.
Yamagata Prefectural Central Hospital · JPKurume University · JPYamagata Prefectural University of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinFemaleHumansLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralRituximabT-Lymphocytes, Helper-InducerAntineoplastic Agents, ImmunologicalBrentuximab VedotinRituximab

Identifiers

PMID34427738
OpenAlexW3193853592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.